WILLIAM GIBSON: Open Payments
NPI 1205047578 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,673 in 139 payments from 27 companies in 2025. Trend: 2023 $2,675 · 2024 $2,574 · 2025 $2,673
Food & beverage: $2,673
| Company | Payments | Amount |
|---|---|---|
| Ardelyx, Inc. | 13 | $297 |
| AstraZeneca Pharmaceuticals LP | 10 | $239 |
| Amgen Inc. | 18 | $233 |
| Lilly USA, LLC | 10 | $185 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $179 |
| Sumitomo Pharma America, Inc. | 7 | $150 |
| Viatris Specialty LLC | 10 | $147 |
| Axsome Therapeutics, Inc. | 7 | $136 |
| Novo Nordisk Inc | 6 | $124 |
| Lundbeck LLC | 5 | $111 |
Products named: IBSRELA, AIRSUPRA, OTEZLA, CAPLYTA, REXULTI, GEMTESA, YUPELRI, Auvelity.
Industry payments across LA — which companies pay providers there.
